Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Quantitative In Vivo 68Ga-Fibroblast-Activation-Protein-Inhibitors (FAPI)-46 PET Imaging of Cancer-Associated Fibroblasts (CAFs) in Pancreatic Ductal Adenocarcinoma (PDA)

NCT05518903 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT05518903
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05518903 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Quantitative In Vivo 68Ga-Fibroblast-Activation-Protein-Inhibitors (FAPI)-46 PET Imaging of Cancer-Associated Fibroblasts (CAFs) in Pancreatic Ductal Adenocarcinoma (PDA)
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Recruiting
Start date
November 15, 2022
Completion date
June 30, 2028
Enrollment
130 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

localized pancreatic adenocarcinoma, resectable pancreatic ductal adenocarcinoma, stage 0 pancreatic cancer ajcc v8, stage i pancreatic cancer ajcc v8, stage iia pancreatic cancer ajcc v8